article thumbnail

Interview: Is global AI regulation really revolutionizing pharma and clinical trials?

Outsourcing Pharma

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

article thumbnail

Interview: Is global AI regulation really revolutionizing pharma and clinical trials?

Outsourcing Pharma

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Rivus raises $132m to advance clinical development of obesity treatment

Pharmaceutical Technology

The CMAs of the company can lower fat throughout the body through mitochondrial uncoupling, a natural process that causes energy regulation. The post Rivus raises $132m to advance clinical development of obesity treatment appeared first on Pharmaceutical Technology.

article thumbnail

What Are the Top Oncology Clinical Trial Trends Through the Lens of ESMO?

XTalks

They discussed the top new trends in oncology trial design that sponsors are either incorporating into clinical trials or need to start planning to include. Evolution in Oncology Clinical Trial Design Recent discussions at ESMO highlight a shift in how clinical trials are designed and conducted.

article thumbnail

Diversity, Equity, and Inclusion Data Service for clinical development 

Drug Discovery World

Otis Johnson, Principal Consultant, Trial Equity, said: “With the FDA issuing guidance to address failings in clinical trial diversity, sponsors are under increasing pressure to improve protocol design.

article thumbnail

Patient groups issue call to action on patient-centric clinical trials

Drug Discovery World

A new whitepaper has introduced the concept of ‘cross-over’ options in cancer clinical trials, as a way to make trials more patient-centric in design. It also encourages sponsors, investigators and regulators to advance patient-centric trial designs.

article thumbnail

IQVIA’s report card for clinical trial diversity: must do better

pharmaphorum

The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated and ethnically diverse populations became even more apparent. The post IQVIA’s report card for clinical trial diversity: must do better appeared first on.